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Abstract
Background: Tumor lysis syndrome is a rare and potentially fatal complication of oncologic treatments, especially
in solid tumors. To the best of our knowledge, tumor lysis syndrome has never been reported after trastuzumab
and pertuzumab combination therapy. Knowledge of risk factors and active prevention proceedings is of utmost
importance to avoid fatal outcomes.
Case presentation: We present the case of a chemo-naive 58-year-old Belgian woman developing hypovolemic
shock and multiple organ failure due to tumor lysis syndrome after a single dose of trastuzumab and pertuzumab
in the context of the treatment of a metastatic breast cancer and resulting in fatal outcome despite optimal
management.
Conclusions: Considering that targeted cancer therapies become increasingly effective, oncologists should be
extremely cautious when treating patients at high risk of tumor lysis syndrome, even if they are not treated with
cytotoxic chemotherapy, and determine appropriate prophylaxis.
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Background
Tumor lysis syndrome (TLS) is a rare complication of
oncologic treatments in solid tumors. It results from
rapid lysis of tumor cells and release of intracellular ma-
terials into the bloodstream. We report a case of TLS
which occurred after a single dose of trastuzumab and
pertuzumab in the context of metastatic breast cancer in
a chemo-naive patient. To the best of our knowledge,
TLS has never been reported after trastuzumab and per-
tuzumab combination therapy.
Case presentation
A 58-year-old Belgian woman was admitted to our hos-
pital with complaints of anorexia, fatigue, and dyspnea.
A right breast cancer had been diagnosed 1 month be-
fore. It was an invasive grade III ductal carcinoma, with
no expression of hormone receptors and with human
epidermal growth factor 2 (HER2) amplification. The
disease was locally advanced with massive invasion of
the chest wall, bilateral axillary lymph node involvement,
pulmonary metastases, and bulky liver metastases. A
weekly paclitaxel, trastuzumab, and pertuzumab sched-
ule was planned as first-line chemotherapy. Our patient
had a medical history of pulmonary tuberculosis.
At admission, pulmonary examination showed
hypoventilation of the right pulmonary basis. A right
pleural effusion was demonstrated by a computed tom-
ography (CT) scan, complicated by a right inferior pneu-
monia. The chest wound was infected by multiple
Gram-negative bacilli. Pleural effusion was punctured,
and its culture was sterile. Blood tests at admission
showed a high C-reactive protein level (126 mg/L), hy-
peruricemia (55 mg/dL), high lactate dehydrogenase
(983 U/L) and uric acid (12 mg/dL) levels and decreased
glomerular filtration rate (53 mL/min), probably due to
dehydration. Her urine analysis was normal. Our patient
received empiric antibiotic therapy with amoxicillin and
clavulanic acid.
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Four days later she developed respiratory distress. No
pulmonary embolism was demonstrated on the CT scan
performed in the emergency department, and symptoms
were attributed to the pleural effusion and right pneu-
monia. Our patient was treated 1 day later with a first
course of trastuzumab and pertuzumab. The infusion of
paclitaxel was delayed due to the infectious context and
was planned to be given later.
On day 2 of the first course of trastuzumab and pertu-
zumab, she developed refractory hypovolemic shock.
Her blood tests showed grade 2 hyperkaliemia (6.4
mmol/L), hyperuricemia (11.4 mg/dL), high lactate de-
hydrogenase (2473 U/L), grade 3 hypocalcemia (1.73
mmol/L), hyperphosphatemia (1.64 mmol/L), and wors-
ening of the acute renal failure (38 mL/min glomerular
filtration rate). Blood gas analysis revealed metabolic
acidosis with a pH of 7.11 and lactate at 10.9 mmol/L. A
diagnosis of TLS induced by the targeted therapy was
made. She was admitted in the intensive care unit where
she received vigorous volume expansion and vasopres-
sors. Despite optimal management, her laboratory values
and hypovolemic shock did not improve and she died 2
days later due to multiple organ failure.
Discussion
TLS is a rare entity. Its incidence is not known but may
be less than 0.3 % in solid tumors in a single-center
study [1]. It is a potentially fatal oncologic emergency
characterized by severe electrolyte and metabolite abnor-
malities secondary to rapid and massive lysis of tumor
cells and release of intracellular components into the
bloodstream, overwhelming the excretion capacities of
the kidneys and leading to hyperuricemia, hyperkalemia,
hyperphosphatemia, and secondary hypocalcaemia.
These electrolytic abnormalities explain the clinical
symptoms. Hyperuricemia and hyperphosphatemia can
lead to acute renal injury by way of uric acid precipita-
tion and calcium phosphate deposition in the renal tu-
bules. Hypocalcemia and hyperkalemia potentially lead
to electrocardiogram (ECG) abnormalities and cardiac
arrhythmias, neuromuscular symptoms, and seizures.
Our patient responded to the diagnostic criteria of la-
boratory TLS (detailed in Table 1), as the three labora-
tory criteria were present and the worsening of acute
renal failure to grade I responds to the definition of clin-
ical TLS criteria established by Cairo and Bishop in 2004
[2] (detailed in Table 2). It is important to note that TLS
is defined as the presence of at least two or more bio-
chemical variables within the 3 days before chemother-
apy or 7 days after chemotherapy in the face of adequate
hydration and use of uric acid-lowering agent. Of note,
neither targeted treatments nor local therapies are ex-
cluded from this definition. Symptoms are observed
more commonly within the 12 to 72 hours after the ini-
tiation of the treatment [2].
Moreover, patients at risk of TLS are classified in low-,
intermediate- and high-risk categories [3].
Solid tumors are by default classified in the low-risk
category but the presence of pre-existing risk factors,
high tumor burden, high sensitivity to antitumoral treat-
ment, and efficacy of the therapies could classify them in
the intermediate- or high-risk group [3, 4].
Tumor and patient-related risk factors of TLS in solid
tumors previously described are bulky disease, extensive
metastases, high proliferative rate, high sensitivity to an-
ticancer therapy, type of anticancer therapy (e.g., using a
combination therapy), elevated LDH, serum creatinine,
uric acid, phosphate at baseline, low urinary flow, dehy-
dration, preexisting nephropathy, extrinsic compression
of the urinary tract by the tumor, and exposure to
nephrotoxins. Some authors think that metastatic dis-
ease and particularly metastases in the liver should be a
relevant risk factor, irrespective of the liver function, and
maybe due to impaired uric acid metabolism and high
purine pools [5, 6].
Our patient presented multiple risk factors: elevated
uric acid, elevated LDH, elevated creatinine, exposure to
nephrotoxins (contrast agents 2 days before), extensive
liver metastases, and bulky disease.
Assessment of risk factors is of utmost importance be-
cause recognition of high risk of TLS should lead to
more active prevention. Regarding this patient, TLS is
not usual in solid tumors, and in particular in breast tu-
mors but the high effectiveness of the trastuzumab and
pertuzumab association could have been the trigger. A
fatal outcome might have been avoided in this case, es-
pecially as it has been demonstrated that clinical TLS
(but not laboratory TLS) is associated with an increased
death rate (83 % vs 24 %; p < 0.001) [7]. Moreover, de-
velopment of acute kidney injury associated with TLS is
a strong predictor of death [8]. Irrespective of the cancer
type, there is a 20–50 % increase in mortality for undiag-
nosed or late-diagnosed TLS in solid tumors [9]. The
best management for TLS is prevention.
TLS prophylaxis should depend on the risk group in
which a patient is classified. Low-risk disease should
simply be monitored and no prophylaxis is required.
While the prophylactic approach for intermediate-risk
patients is still not clearly defined [6], it is recommended
to monitor these cases for TLS; they should receive
Table 1 Laboratory Tumor Lysis Syndrome criteria
Variable Value Change from baseline value
Uric acid ≥8 mg/dL (476 mmol/L) 25 % increase
Potassium ≥6 mEq/L (or 6 mmol/L) 25 % increase
Phosphorus ≥4.5 mg/dL (1.45 mmol/L) 25 % increase
Calcium ≤7 md/dl (1.75 mmol/L) 25 % increase
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increased hydration (3 l/m2 per day) and be adminis-
tered allopurinol (100–300 mg, orally, every 8 hours,
daily). In the group at high risk of developing TLS, pa-
tients should be monitored more frequently (possibly in
an intensive care unit), receive increased hydration (3 l/
m2 per day) unless evidence of renal insufficiency and
oliguria, loop diuretics if necessary, and rasburicase
(0.1–0.2 mg/kg for one dose and repeated if needed
seems to be the most cost-effective approach) [3]. Urine
alkalinization is no longer recommended: it has not been
shown to be superior to the administration of normal sa-
line alone and might even be harmful [4, 10].
Unfortunately, despite appropriate prophylactic mea-
sures, about 3 to 5 % of high-risk patients receiving
chemotherapy will develop TLS [11].
TLS was previously well described in hematologic ma-
lignancies, but as treatments become more efficient, it is
becoming increasingly frequent in solid tumors, which
previously had been rarely associated with this complica-
tion [12]. Chemotherapy is the most frequent etiology of
TLS (58 %), but TLS was also described with multiple
anticancer treatments such as radiotherapy, restrictive
surgical procedures, immunotherapy, endocrine therapy,
radiofrequency ablation, chemoembolization, bisphopho-
nates, and glucocorticoid therapy alone. In addition, TLS
can occur spontaneously due to tumor necrosis prior to
any therapy [5]. Case reports involving targeted therap-
ies such as tyrosine kinase inhibitors or cyclin-
dependent kinases, where TLS was a dose-limiting tox-
icity in phase I trials, and monoclonal antibodies are in-
creasingly often described [13]. One case of TLS has
been reported after trastuzumab alone [14]. To the best
of our knowledge, TLS has never been described with
the association of trastuzumab and pertuzumab. As
shown in the NeoSphere trial, this association is highly
effective, as without any chemotherapy, its use in oper-
able, locally advanced or inflammatory breast cancer
leads to a pathological complete response rate (pCR) of
16.8 % in the breast (Gianni et al.) [15]. Based on these
encouraging results, a randomized phase II study led by
the EORTC Cancer in the Elderly Task Force and the
EORTC Breast Cancer Group is currently investigating
the use of trastuzumab and pertuzumab (with or without
metronomic chemotherapy) in elderly metastatic breast
cancer patients. The use of targeted therapies alone in
breast cancer is thus becoming increasingly popular be-
cause of its relative tolerance and high efficacy. As exem-
plified in this case report, oncologists should be cautious
when using these drugs in patients at high risk of TLS.
Conclusions
We here describe the first case of TLS in a patient with
metastatic breast cancer with the association of trastuzu-
mab and pertuzumab. As targeted cancer therapies be-
come increasingly effective, oncologists treating breast
cancer patients should be extremely cautious when treat-
ing patients at high risk of TLS, even if they are not
treated with cytotoxic chemotherapy.
As TLS can unfortunately lead to a fatal outcome, phy-
sicians should take into account the risk of TLS before
the initiation of any anticancer treatment, and determine
appropriate prophylaxis.
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